In this issue:
Early vs late anti-TNF induction in mild-tomoderate UC
AVX-470 for active UC
Secukinumab for active psoriatic arthritis
Adalimumab and work-related outcomes in RA
Ustekinumab in anti-TNF refractory CD
Vedolizumab induction therapy in IBD
Please login below to download this issue (PDF)